207 related articles for article (PubMed ID: 37180104)
1. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.
Tang L; Kong Y; Wang H; Zou P; Sun T; Liu Y; Zhang J; Jin N; Mao H; Zhu X; Wang J; Meng F; You Y
Front Immunol; 2023; 14():1145441. PubMed ID: 37180104
[TBL] [Abstract][Full Text] [Related]
2. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
[TBL] [Abstract][Full Text] [Related]
3. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H
Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245
[TBL] [Abstract][Full Text] [Related]
4. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
5. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
El Khawanky N; Hughes A; Yu W; Myburgh R; Matschulla T; Taromi S; Aumann K; Clarson J; Vinnakota JM; Shoumariyeh K; Miething C; Lopez AF; Brown MP; Duyster J; Hein L; Manz MG; Hughes TP; White DL; Yong ASM; Zeiser R
Nat Commun; 2021 Nov; 12(1):6436. PubMed ID: 34750374
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
Front Immunol; 2021; 12():782448. PubMed ID: 34868059
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
9. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
10. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Schmelz K; Wagner M; Dörken B; Tamm I
Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
[TBL] [Abstract][Full Text] [Related]
11. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
12. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
[TBL] [Abstract][Full Text] [Related]
15. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
17. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
[TBL] [Abstract][Full Text] [Related]
19. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
Front Immunol; 2020; 11():1787. PubMed ID: 32973749
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
Labrador J; Martínez-Cuadrón D; de la Fuente A; Rodríguez-Veiga R; Serrano J; Tormo M; Rodriguez-Arboli E; Ramos F; Bernal T; López-Pavía M; Trigo F; Martínez-Sánchez MP; Rodríguez-Gutiérrez JI; Rodríguez-Medina C; Gil C; Belmonte DG; Vives S; Foncillas MÁ; Pérez-Encinas M; Novo A; Recio I; Rodríguez-Macías G; Bergua JM; Noriega V; Lavilla E; Roldán-Pérez A; Sanz MA; Montesinos P; On Behalf Of Pethema Group
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
